GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADMA Biologics Inc (NAS:ADMA) » Definitions » Shiller PE Ratio

ADMA Biologics (ADMA Biologics) Shiller PE Ratio : (As of May. 12, 2024)


View and export this data going back to 2013. Start your Free Trial

What is ADMA Biologics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ADMA Biologics Shiller PE Ratio Historical Data

The historical data trend for ADMA Biologics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADMA Biologics Shiller PE Ratio Chart

ADMA Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ADMA Biologics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ADMA Biologics's Shiller PE Ratio

For the Biotechnology subindustry, ADMA Biologics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ADMA Biologics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADMA Biologics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ADMA Biologics's Shiller PE Ratio falls into.



ADMA Biologics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ADMA Biologics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, ADMA Biologics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.08/129.4194*129.4194
=-0.080

Current CPI (Dec. 2023) = 129.4194.

ADMA Biologics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.640 99.695 -0.831
201406 -0.430 100.560 -0.553
201409 -0.360 100.428 -0.464
201412 -0.380 99.070 -0.496
201503 -0.370 99.621 -0.481
201506 -0.440 100.684 -0.566
201509 -0.480 100.392 -0.619
201512 -0.450 99.792 -0.584
201603 -0.430 100.470 -0.554
201606 -0.500 101.688 -0.636
201609 -0.340 101.861 -0.432
201612 -0.350 101.863 -0.445
201703 -0.510 102.862 -0.642
201706 -0.550 103.349 -0.689
201709 -0.590 104.136 -0.733
201712 -0.286 104.011 -0.356
201803 -0.390 105.290 -0.479
201806 -0.350 106.317 -0.426
201809 -0.330 106.507 -0.401
201812 -0.390 105.998 -0.476
201903 -0.280 107.251 -0.338
201906 -0.250 108.070 -0.299
201909 -0.190 108.329 -0.227
201912 -0.180 108.420 -0.215
202003 -0.260 108.902 -0.309
202006 -0.230 108.767 -0.274
202009 -0.190 109.815 -0.224
202012 -0.200 109.897 -0.236
202103 -0.160 111.754 -0.185
202106 -0.150 114.631 -0.169
202109 -0.130 115.734 -0.145
202112 -0.090 117.630 -0.099
202203 -0.130 121.301 -0.139
202206 -0.070 125.017 -0.072
202209 -0.080 125.227 -0.083
202212 -0.060 125.222 -0.062
202303 -0.030 127.348 -0.030
202306 -0.030 128.729 -0.030
202309 0.010 129.860 0.010
202312 -0.080 129.419 -0.080

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ADMA Biologics  (NAS:ADMA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ADMA Biologics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of ADMA Biologics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ADMA Biologics (ADMA Biologics) Business Description

Traded in Other Exchanges
N/A
Address
465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Executives
Alison Cecily Finger director C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Jerrold B Grossman director 65 COMMERCE WAY, HACKENSACK NJ 07601
Young Kwon director C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Adam S Grossman director, officer: President and CEO 65 COMMERCE WAY, HACKENSACK NJ 07601
Brian Lenz officer: EVP, CFO 65 COMMERCE WAY, HACKENSACK NJ 07601
Lawrence P. Guiheen director 65 COMMERCE WAY, HACKENSACK NJ 07601
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
James Mond officer: CSO/CMO 65 COMMERCE WAY, HACKENSACK NJ 07601
Biotest Divestiture Trust 10 percent owner C/O ERIC ROSENBACH, TRUSTEE, 402 NORFOLK STREET, CAMBRIDGE MA 02139
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Biotest Pharmaceuticals Corp director, 10 percent owner 5800 PARK OF COMMERCE BLVD., NW, BOCA RATON FL 33487